Canada markets closed

Edwards Lifesciences Corporation (EW)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
76.66+0.88 (+1.16%)
At close: 4:00PM EDT

76.66 0.00 (0.00%)
After hours: 4:47PM EDT

Full screen
Trade prices are not sourced from all markets
Previous Close75.78
Open76.47
Bid75.96 x 800
Ask76.76 x 800
Day's Range75.55 - 77.60
52 Week Range51.51 - 82.55
Volume1,990,423
Avg. Volume2,969,618
Market Cap47.663B
Beta (5Y Monthly)0.88
PE Ratio (TTM)65.13
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients

    Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients. This approval was granted following an interim order issued by Health Canada to address the pressing need for medical supplies used in the response to the COVID-19 pandemic. Hemodynamic monitoring refers to the measurement and tracking of different vital signs that help manage blood flow and oxygenation in critically ill patients, like those who are being treated for COVID-19.

  • ACCESSWIRE

    Edwards Lifesciences Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 23, 2020 / Edwards Lifesciences Corp. (NYSE:EW) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 23, 2020 at 5:00 ...

  • GlobeNewswire

    Koa Accel Launches as New Type of Medical Device Accelerator, Embedding Expert, Invested Teams to Drive Innovations Forward, Faster, to Reduce Investor Risk

    In a move to develop medical devices faster, at a lower cost, and with a greater likelihood of a successful exit, Koa Accel today announced its launch as a next generation medical device accelerator. While mentorship and access to a modicum of business services is the cornerstone of most accelerators, Koa embeds an experienced team covering all of the critical areas of early stage medical device development. This allows Koa to fail fast or rapidly advance the venture as a de-risked startup.